Prognostic significance of factors recorded at the time of AHA diagnosis: univariate and multivariate analysis
| Factors at AHA Diagnosis . | N . | Univariate Analysis . | Multivariate Analysis . | ||
|---|---|---|---|---|---|
| % Surviving at 5 y . | P Value . | P Value . | Hazard Ratio (95% CI) . | ||
| Age (y) | |||||
| > 65 | 31 | 43 | |||
| ≤ 65 | 21 | 31 | .45 | — | — |
| Sex | |||||
| M | 44 | 41 | |||
| F | 8 | 18 | .48 | — | — |
| Hb (g/dL) | |||||
| ≤ 8 | 21 | 39 | |||
| > 8 | 31 | 35 | .58 | — | — |
| Lymph × 109/L | |||||
| ≤ 60 | 28 | 24 | |||
| > 60 | 24 | 59 | .13 | — | — |
| Plts × 109/L | |||||
| ≤ 100 | 7 | 36 | |||
| > 100 | 45 | 36 | .43 | — | — |
| AeAb | |||||
| IgG | 45 | 763-150 | |||
| IgM | 7 | 213-150 | .02 | .02 | 5.25 |
| (1.74-15.83) | |||||
| Previous therapy for CLL | |||||
| Yes | 13 | 16 | |||
| No | 39 | 43 | .03 | .54 | — |
| Infection prophylaxis | |||||
| Yes | 29 | 32 | |||
| No | 23 | 35 | .26 | — | — |
| AHA at the time of CLL diagnosis | |||||
| Yes | 19 | 66 | |||
| No | 33 | 21 | 0.04 | 0.02 | 2.78 |
| (1.11-6.96) | |||||
| Factors at AHA Diagnosis . | N . | Univariate Analysis . | Multivariate Analysis . | ||
|---|---|---|---|---|---|
| % Surviving at 5 y . | P Value . | P Value . | Hazard Ratio (95% CI) . | ||
| Age (y) | |||||
| > 65 | 31 | 43 | |||
| ≤ 65 | 21 | 31 | .45 | — | — |
| Sex | |||||
| M | 44 | 41 | |||
| F | 8 | 18 | .48 | — | — |
| Hb (g/dL) | |||||
| ≤ 8 | 21 | 39 | |||
| > 8 | 31 | 35 | .58 | — | — |
| Lymph × 109/L | |||||
| ≤ 60 | 28 | 24 | |||
| > 60 | 24 | 59 | .13 | — | — |
| Plts × 109/L | |||||
| ≤ 100 | 7 | 36 | |||
| > 100 | 45 | 36 | .43 | — | — |
| AeAb | |||||
| IgG | 45 | 763-150 | |||
| IgM | 7 | 213-150 | .02 | .02 | 5.25 |
| (1.74-15.83) | |||||
| Previous therapy for CLL | |||||
| Yes | 13 | 16 | |||
| No | 39 | 43 | .03 | .54 | — |
| Infection prophylaxis | |||||
| Yes | 29 | 32 | |||
| No | 23 | 35 | .26 | — | — |
| AHA at the time of CLL diagnosis | |||||
| Yes | 19 | 66 | |||
| No | 33 | 21 | 0.04 | 0.02 | 2.78 |
| (1.11-6.96) | |||||
Percent surviving at 2 years.
AeAb indicates antierythrocyte antibody; Hb, hemoglobin; Lymph, lymphocytes; Plts, platelets.